UPPSALA, Sweden, April 10, 2025 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate ...

The financial terms of the deal were not disclosed, but TigaTx will become a wholly owned subsidiary of Epsilogen as part of ...

Epsilogen completes acquisition of TigaTx to create world’s leading pan-isotype cancer antibody company: London Tuesday, April 8, 2025, 10:00 Hrs [IST] Epsilogen, the global lea ...

The combined company will clinically advance Epsilogen's MOv18 IgE antibody in ovarian cancer and TigaTx's anti-EGFR IgA antibody.

UK-based developer of novel immunoglobulin E (IgE) antibodies to treat cancer, Epsilogen, says it has completed the ...

U.K.-based Epsilogen has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer ...

UK biotech Epsilogen has bought US-based TigaTx, pooling their resources to create what it says will be a leader in ...

Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.

FDA grants accelerated approval to Novartis' Vanrafia for IgA nephropathy, with Phase 3 data in 2026 expected to support ...

Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US ...

PRINCETON, NJ, USA & TOKYO, Japan I March 31, 2025 I Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd.